Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on April 14th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
- Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
- Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
- Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
- Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
- Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
- Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
- Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
- Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
- Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.
Vaxcyte Stock Performance
Shares of Vaxcyte stock traded down $0.76 during trading on Tuesday, hitting $30.83. 153,529 shares of the stock were exchanged, compared to its average volume of 1,308,453. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock's fifty day moving average is $45.81 and its 200 day moving average is $73.63. The stock has a market cap of $3.98 billion, a PE ratio of -6.68 and a beta of 1.27.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the firm posted ($0.85) EPS. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on PCVX shares. Guggenheim reiterated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Bank of America reduced their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, The Goldman Sachs Group dropped their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and a consensus target price of $136.50.
Check Out Our Latest Research Report on Vaxcyte
Insider Buying and Selling
In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Vaxcyte
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. Wells Fargo & Company MN lifted its position in shares of Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after buying an additional 25,257 shares during the last quarter. Diversified Trust Co bought a new stake in Vaxcyte in the fourth quarter worth approximately $1,433,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Vaxcyte by 23.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after buying an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after purchasing an additional 144,516 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Vaxcyte by 70.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after buying an additional 246,049 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
